Compare OPK & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPK | PHAR |
|---|---|---|
| Founded | 2006 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2011 | 2020 |
| Metric | OPK | PHAR |
|---|---|---|
| Price | $1.48 | $11.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $1.60 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 4.4M | 19.2K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $606,879,000.00 | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | $4.24 | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.98 | $9.62 |
| 52 Week High | $1.73 | $21.34 |
| Indicator | OPK | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 60.33 | 46.43 |
| Support Level | $1.25 | $9.62 |
| Resistance Level | $1.58 | $13.51 |
| Average True Range (ATR) | 0.06 | 0.60 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 95.00 | 53.28 |
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.